I.N. HOLDINGS Role in Cell Facility and Production Management

Production and Management of Stem Cell and Stem Cell-Derived Exosomes

I.N. HOLDINGS oversees certified cell facilities in Japan, meeting GMP/GLP standards to produce high-quality exosome-based therapeutics and cosmetics.

Advancing Exosome Therapeutic Development

To develop exosome-based therapeutics and cosmetics, we leverage I.N. HOLDINGS’ expertise in managing licensed cell facilities and GMP/GLP-compliant production. With limited in-house resources, we rely on I.N. HOLDINGS as an experienced partner to ensure stable production and stringent quality management.

See more (Coming soon)

Utilization Plan

■ Clinical Trials: Partner with licensed clinics in Japan, with I.N. HOLDINGS overseeing production management, to ensure exosome therapeutics are produced in certified facilities, maintaining safety and consistent quality.
■ Post-Trial Production: Following successful trials, manufacture therapeutics and cosmetics for various applications, including skin and hair loss treatments, based on the validated exosome therapeutics.

See more (Coming soon)